Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Revenue of Amyris, Inc. (AMRS)
Revenue in 2022 (TTM): $269.85 M
According to Amyris, Inc.'s latest financial reports the company's current revenue (TTM) is $269.85 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Amyris, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $269.85 M | $11.18 M | $-514,205,000 | $-538,625,000 | $-535,928,000 |
| 2021 | $341.82 M | $186.68 M | $-190,797,000 | $-272,311,000 | $-264,197,000 |
| 2020 | $173.14 M | $85.33 M | $-200,457,000 | $-323,850,000 | $-324,143,000 |
| 2019 | $152.56 M | $76.37 M | $-141,826,000 | $-242,138,000 | $-242,767,000 |
| 2018 | $80.42 M | $41.51 M | $-112,741,000 | $-211,349,000 | $-211,349,000 |
| 2017 | $143.45 M | $79.62 M | $-41,216,000 | $-77,096,000 | $-77,391,000 |
| 2016 | $77.19 M | $20.51 M | $-115,828,000 | $-86,781,000 | $-87,334,000 |
| 2015 | $34.15 M | $-3,221,000 | $-118,463,000 | $-217,584,000 | $-217,952,000 |
| 2014 | $43.27 M | $10.07 M | $-225,615,000 | $2.66 M | $2.29 M |
| 2013 | $41.12 M | $2.87 M | $-5,610,000 | $-235,754,000 | $-235,111,000 |
| 2012 | $73.69 M | $-3,620,000 | $-200,126,000 | $-205,052,000 | $-205,139,000 |
| 2011 | $146.99 M | $-8,624,000 | $-166,553,000 | $-178,959,000 | $-178,870,000 |
| 2010 | $80.31 M | $9.8 M | $-81,525,000 | $-80,826,000 | $-81,870,000 |
| 2009 | $64.61 M | $4.18 M | $-51,418,000 | $-64,800,000 | $-64,459,000 |
| 2008 | $13.89 M | $3.53 M | $-39,395,000 | $-42,543,000 | $-41,864,000 |